A PSA result above the reference range sets off a very particular kind of fear, usually before anyone has explained what the test can and cannot show. PSA is a protein made by the prostate — not by cancer specifically. It rises with cancer, but also with age, size, infection, cycling and even sex the night before. The number is a reason to look further, not a diagnosis.
What you'll read
What PSA actually measures
Prostate-specific antigen is made by normal prostate tissue and leaks into the blood in small amounts. Anything that disturbs the gland increases the leak. There is no single threshold that separates cancer from no cancer; a value of 4 ng/mL is a common trigger for further tests, but plenty of cancers occur below it and most men above it are cancer-free.
What matters more than a single figure is the trend. Two readings taken weeks apart, and the rate at which the value is climbing, tell a urologist far more than one number in isolation. Free-to-total PSA ratio and PSA density, which corrects for gland size, refine the picture further.
What else raises the number
- Benign prostatic enlargement — extremely common after 50 and the single most frequent explanation
- Prostatitis or a urinary infection, which can raise PSA dramatically for weeks
- Ejaculation within 48 hours of the blood test
- A long bicycle ride, or a recent rectal examination or catheter
- Age itself: the normal range drifts upward decade by decade
What happens next: MRI before biopsy
The pathway has changed significantly in the last decade. Instead of proceeding straight to a random biopsy, guidelines now recommend a multiparametric MRI first. The scan is scored from 1 to 5; a low score can spare a man a biopsy altogether, while a suspicious area can be targeted precisely rather than sampled blindly. Targeted biopsy finds more of the cancers that matter and fewer of the ones that never would have caused harm.
If cancer is found — not all of it needs treating
Prostate cancer is graded by the Gleason score, now reported as ISUP grade groups 1 to 5. Grade group 1 disease confined to the gland is often managed by active surveillance: regular PSA, repeat MRI and biopsy, with treatment only if the disease shows it is progressing. This avoids the incontinence and erectile problems that follow surgery or radiotherapy, in men whose cancer might never have troubled them.
Questions to ask before agreeing
- Should the PSA be repeated first, and after how long?
- Has infection been ruled out or treated before the value is acted on?
- Will I have an MRI before any biopsy, and will the biopsy be targeted?
- If cancer is found, what is my grade group and stage, and am I a candidate for active surveillance?
- For treatment, what is this surgeon's or centre's annual volume, and what are their continence and potency results?
Frequently asked questions
At what age should I start PSA testing?
Most guidelines suggest a shared decision from around age 50, or from 40 to 45 for men with a family history of prostate cancer, African ancestry or a known BRCA mutation. It is a conversation about your risk, not an automatic annual test.
Is a prostate biopsy painful or risky?
It is uncomfortable rather than painful, done under local anaesthetic and taking around fifteen minutes. The main risk is infection, which is why the transperineal route, now standard in many centres, has largely replaced the transrectal approach.
My PSA is high but the MRI is clear. What now?
That combination usually points to benign enlargement or inflammation. The standard response is monitoring: repeat PSA in a few months, treat any infection, and repeat imaging only if the value keeps climbing. Immediate biopsy is not automatic in this situation.
High PSA and unsure what to do next?
Send your PSA results, MRI report and any biopsy findings. A urologic oncologist will tell you whether the next step proposed to you is the one the guidelines recommend.